Despite preliminary evidence of clinical activity of the putative differentiating agent sodium phenylbutyrate (PB) in the treatment of myeloid neoplasms, it has proven difficult to maintain therapeutic levels of PB above 0.5 mM, well below the ED 50 of 1-2 mM. We have studied the impact of combining PB with alltrans retinoic acid (ATRA) on the ML-1 myeloid leukemia cell line. ATRA augmented PB-induced differentiation, cell-cycle arrest, and apoptosis. ATRA augmented PB induction of the myelomonocytic marker CD11b at all doses of ATRA tested (0.0025-1 M). Although ATRA did not significantly affect the ED 50 of PB, the combination of ATRA (1 M) and PB (0.5 mM) augmented PB-induced CD11b expression eight-fold. Compared to PB alone, this combination of ATRA and PB induced greater cell cycle arrest (S-phase 14% vs 38%; G 0 /G 1 -phase cells 72% vs 52%) and greater apoptosis (24% vs 16% by TUNEL assay). Treatment with ATRA (0.5 M) in combination with PB (0.5 mM) led to significantly greater inhibition of colony formation (4.8% vs 48% inhibition). ATRA combined synergistically with PB to augment CD11b expression and inhibit colony formation. This combination also showed significant interaction in terms of S-phase inhibition. However, this interaction varied as a function of ATRA concentration: antagonistic at low concentrations of ATRA, synergistic at higher concentrations of ATRA. These data suggest that retinoids may significantly augment the cytostatic and differentiating activity of PB, leading to increased potency of the latter drug at clinically achievable doses.
Introduction
The aromatic fatty acids phenylacetate (PA) and phenylbutyrate (PB) induce differentiation and growth inhibition in a variety of malignancies, including myelodysplastic syndromes, colon cancer, prostate cancer, and neuroblastoma, both in vitro and in vivo. [1] [2] [3] [4] [5] [6] Although the most important molecular mechanisms of PB have not yet been elucidated, evidence suggests that PB affects DNA methylation, 7 histone acetylation, 8 protein isoprenylation, 9 and expression of peroxisome proliferator-activated receptors. 10 In the ML-1 myeloid leukemia cell line, PB has been shown to induce G 1 arrest, accompanied by p21 WAF1/CIP1 induction and decreased Rb phosphorylation. 53 ML-1 cells can be induced to differentiate in granulocyte or monocytic lineages in response to many stimuli including phorbol ester, low doses of chemotherapy, and growth factors. 11, 12 The ML-1 cell line, which is p53 wildtype, 13 may more faithfully reflect primary human disease than p53 null cell lines typically used as models for differentiation, including HL-60, since primary myeloid leukemic blasts and myelodysplasia (MDS) cells do not typically harbor p53 abnormalities.
In phase I trials for the treatment of acute myeloid leukemia (AML) and MDS, PB has demonstrated promising hematologic effects, including increases in platelet and neutrophil counts, and decreases in circulating blasts. 15 Dose escalation beyond the maximal tolerated dose of 375 mg/kg/day produced central nervous system toxicity; intravenous continuous administration at the maximal tolerated dose yields steady-state plasma levels of р0.5 mm. 2 Thus, toxicity may preclude the use of PB at pharmacodynamically optimal doses, as in vitro studies in myeloid cell lines indicate an ED50 of 1-2 mm for differentiating activity, and for growth inhibition.
Optimal use of differentiating agents may require combinations of agents with complementary or non-cross-reactant molecular mechanisms analogous to the use of combination chemotherapy. Retinoids have been shown to synergize with sodium butyrate (BA) in the induction of differentiation of HL60 cells. 16 We have recently shown that the biological activities of PB are closer to that of BA than PA. 53 Early studies of 13-cis retinoic acid, 9-cis retinoic acid, and all-trans retinoic acid (ATRA) have suggested limited clinical activity of these agents in MDS. [17] [18] [19] [20] [21] [22] The present studies were undertaken to investigate whether the addition of retinoic acid could improve the pharmacodynamic profile of PB on the ML-1 myeloid leukemia cell model. Our studies show that ATRA acts synergistically with PB to induce differentiation and cell cycle arrest.
Materials and methods

Chemicals
ATRA was obtained from Sigma (St Louis, MO, USA). PB was obtained from Triple Crown America (Perkasie, PA, USA). Trichostatin A (TSA) was purchased from Wako Pure Chemical Industries, Ltd (Richmond, VA, USA).
Cells
ML-1 cells were grown in RPMI 1640 (Sigma) supplemented with 10% newborn bovine serum (NBS; Replicell, Woodcross, UT, USA) at 37°C with 5% CO 2 under humidified conditions. Experiments with retinoids were performed in HITES media (RPMI 1640, 5 mg/l insulin, 5 mg/l transferring, 5 mg/l selenious acid, 10 −8 m hydrocortisone, 10 −8 m 17␤-estradiol; Sigma) with 2% fetal bovine serum (Hyclone, Logan UT, USA).
Differentiation
ML-1 cells were plated at an initial concentration of 50 000 cells/ml in the presence of graded doses of the appropriate drugs.
Following 3 days of culture, the granulocytic/monocytic marker CD11b was measured following staining with R-phycoerythrin-conjugated CD11b antibody (Becton Dickinson, Mountain View, CA, USA; clone D12). Previous studies have shown that 3 day incubation with PB led to maximal effects on differentiation of ML-1 cells. 53 Treated cells labeled with R-phycoerythrin-conjugated Mouse lgG1 antibody (Dako, Glostrup, Denmark; clone DAK-GO1) were used as a negative control. Fluorescence was quantified by FACScan flow cytometer. Mean fluorescence channel was converted to linear mean fluorescence intensity and fluorescence intensity of control antibody staining was subtracted as previously described. 23 
Cell cycle
Cell cycle analysis was performed according to Dolbeare et al's technique 24 following a 2 h pulse with bromodeoxyuridine (BrdU, 10 m, 37°C; Sigma). Cells were fixed in 70% MeOH (−20°C, 5 min), denatured in 0.1 n HCl with 0.7% Triton X-100 (JT Baker, Phillipsburg, NJ, USA) in PBS (0°C, 10 min), then boiled in 0.003 n HCl (10 min) before staining with anti-BrdU monoclonal antibody (Becton Dickinson; clone B44) and propidium iodide (PI) (Sigma). Flow cytometric analysis was then performed.
Apoptosis
Apoptosis was measured using two assays. In the TUNEL assay, 25 cells were fixed for 15 min in 2 ml of cold 1% formaldehyde (ultra-pure, EM grade; Polysciences, Warrington, PA, USA) in PBS. Cells were then washed in PBS, followed by 0.5 ml reaction buffer (200 m sodium cacodylate, 250 g/ml bovine serum albumin, 2.5 mm Tris-HCl, pH 6.6 at 25°C). Cells were resuspended in 50 l of reaction buffer with 0.50 nmol biotinylated dUTP and 5 units terminal deoxynucleotidyl transferase (Boehringer Mannheim, Indianapolis, IN, USA) and incubated for 30 min at 37°C. Cells were then washed in staining buffer composed of 150 mm NaCl, 0.015 m sodium citrate, 0.1% Triton X-100, and 5% powdered milk. Cells were resuspended in 100 l staining buffer containing 50 g/ml fluorescein (FITC)-labeled streptavidin (Dako, Carpinteria, CA, USA) and incubated in the dark for 30 min at room temperature. Cells were washed twice with 0.1% Triton X-100 in PBS, then resuspended in PBS for flow cytometric analysis. HL-60 cells treated with 1.5 m camptothecin (Sigma) overnight prior to processing served as positive control. Identically treated cells assayed in the absence of terminal deoxynucleotidyl transferase served as negative control.
In several experiments, Annexin V staining was used to assess apoptosis (R & D Systems, Minneapolis, MN, USA; Apoptosis Detection Kit, No. KNX50-200). 26 Cells were washed in ice-cold PBS, then incubated on ice in 15 ml of 0.9% NaCl containing 5 mm EDTA for 15 min to remove endogenously bound Annexin V. After, cells were washed in ice-cold PBS, and resuspended in 200 l ice-cold binding buffer (10 mm Hepes, pH 7.4, 150 mm NaCl, 2.5 mm CaCl 2 , 1 mm MgCl 2 , 4% BSA). Cells resuspended in 200 l ice-cold binding buffer with 25 mm EDTA prior to the addition of Annexin V-FITC served as negative control. 10 l of Annexin V-FITC (R & D Systems) was added, and cells were incubated on ice for 10 min in the dark. 10 l of PI was added and incubated for 10 min on ice and in the dark. Cells were then analyzed by flow cytometry. Annexin V + PI − (early apoptotic cells) and Annexin V + PI + cells (late apoptotic and necrotic cells) were both analyzed. Results were similar when total Annexin V + cells were compared with Annexin V + PI − cells (data not shown). We report total Annexin V binding.
Clonogenic assay
Cells were plated in 35 × 10 mm petri dishes (Falcon 1008; BD, Lincoln Park, NJ, USA) at a concentration of 2000 cells/plate in 1.2% methylcellulose, 1% bovine serum albumin, 10% phytohemagglutanin-stimulated, lymphocyte-conditioned media, 30% fetal bovine serum (Hyclone), and 0.1 mm 2-␤-mercaptoethanol. Cells were incubated at 37°C in 5% CO 2 . Colonies were counted 9-12 days after plating. To study the impact of PB + ATRA on clonogenicity, these drugs were incorporated into the methyl cellulose.
Histone acetylation
Cells were harvested, lysed, nuclei isolated, and histones prepared according to published techniques. 27 Protein in each sample was quantified (Bio-Rad, Hercules, CA, USA), and 50 g of total cellular protein was separated by 15% SDS-PAGE. Proteins were transferred on to nitrocellulose membranes, and equivalent transfer was confirmed by fast green staining of membranes. 28 Primary rabbit polyclonal antibodies to human acetylated histone H3 and histone H4 (Upstate Biotechnology, Lake Placid, NY, USA) were used in immunoblots, which were then stained with horseradish peroxidase-conjugated secondary antibodies (Amersham Life Sciences). Autoradiography was carried out using enhanced chemiluminescence (Kodak Scientific Imaging Systems, Rochester, NY, USA).
Statistical analysis
The primary statistical outcomes of this study were CD 11b expression, apoptosis, cell cycle distribution, and colony formation. The variation in each outcome was modeled as a consequence of several variables: effect of inter-experimental variation, effect of PB concentration, effect of retinoid concentration, effect of interaction between PB alone and retinoid alone (PB × retinoid), and effect of interaction between PB alone and retinoid alone varying as a function of retinoid dose (PB × retinoid × retinoid). These variables were assumed to affect each outcome in a linear fashion (analysis of variance). To control for possible systematic, inter-experimental differences, all analyses of variance incorporated a fixed regression effect for each experiment. P values reported test whether or not the estimated effect of the variable or interaction is consistent with zero. All statistical analyses were performed with Statistical Analysis System Version 6.12 (SAS Institute, Cary, NC, USA).
Pharmacodynamic interactions were also analyzed by the Combination Index (Cl) method of Chou and Talalay. Cl Ͻ 1 indicates synergy. Cl Ͼ 1 indicates antagonism, and Cl = 1 indicates additive interaction. 29 Means were compared using paired, two-tailed Student's t-test.
Results
Differentiation
To test the impact of ATRA on PB-induced differentiation, ML-1 cells were cultured in the presence of graded concentrations of PB in the presence or absence of ATRA. As previously described, treatment with PB alone led to induction of expression of the myelomonocytic marker CD11b in a dosedependent fashion. Exposure of cells to combinations of PB and ATRA led to greater induction of CD11b expression than PB or ATRA alone (Figure 1 ). When cells were exposed to 1 m ATRA in combination with 0.5 mm PB (the maximal sustainable clinical concentration of PB), ATRA augmented PB induced CD11b expression nearly eight-fold (52.5 vs 6.9, P = 0.013) (Figure 1a ). When exposed to a fixed ratio of PB:ATRA (1000:1), analysis of the combination index confirmed synergy (Cl Ͻ 1) at all doses tested (Figure 1b , Table 1 ). Multivariate regression was performed on 11 experiments in which cells were exposed to various combinations of ATRA and PB (Table  2 ). CD11b expression varied as a function of PB dose and ATRA dose (Table 2 ). In addition, a significant interaction effect between PB and ATRA (PB × ATRA) was found, confirming the synergistic interaction found by combination index ( Table 2) .
Cell cycle
As expected, treatment with PB alone or ATRA alone caused cell cycle arrest, characterized by a decrease in the percentage of cells in S-phase (Figure 2a) , and a corresponding increase in cells in G 0 /G 1 -phase (data not shown). In contrast to their effects on CD11b induction (synergistic at all doses tested), the impact of combinations of PB and ATRA on Sphase inhibition varied as a function of ATRA concentration. In cells treated with 1 m ATRA in combination with 0.5 mm PB, ATRA augmented PB-induced S-phase reduction (14% vs 38%, P = 0.0013) (Figure 2a) and G 0 /G 1 -phase accumulation (72% vs 52%, P = 0.002); however, the combination of PB and ATRA led to less cell cycle inhibition than ATRA alone at doses of PB less than 0.5 mm (Figure 2a) . PB alone appeared to stimulate proliferation slightly at these low doses.
Combinations of PB and RA at a fixed ratio of PB:RA (1000:1) were antagonistic at low doses of ATRA, producing an effect on S-phase inhibition intermediate between that of ATRA alone and PB alone (Figure 2b) . At higher doses, the two drugs interacted synergistically. Analysis of combination index confirmed antagonism (Cl Ͼ 1) at low doses, and synergy (Cl Ͻ 1) at higher doses (Table 3 ). Multivariate regression of 11 experiments confirmed the significant impact of PB alone and ATRA alone on cell cycle arrest, as well as a significant interaction between PB and ATRA, which varied as a function of ATRA dose (PB × ATRA × ATRA, Table 2 ).
Apoptosis
Both PB and ATRA induced apoptosis in ML-1 cells in a dosedependent manner ( Figure 3 , Table 2 ). In combination, ATRA (1 m) significantly augmented PB (0.5 mm) induced apoptosis (24% vs 16%, P Ͻ 0.01, Figure 3) . However, no significant interaction between the two drugs was seen in terms of apoptosis induction, either by Cl (data not shown) or by regression analysis (Table 2 ). 
Colony formation
ATRA and PB both significantly inhibited the clonogenic potential of ML-1 cells (Figure 4) . In contrast to their biphasic interaction with respect to cell cycle arrest, PB and ATRA synergistically inhibited colony formation at doses tested уPB 0.25 mm (Tables 2 and 4 ). When cells were exposed to 0.5 m ATRA in combination with 0.5 mm PB, colony formation inhibition by PB was augmented 10-fold compared to PB alone (4.8 vs 47.9, P Ͻ 0.001) (Figure 4 ).
Histone acetylation
Recent data have demonstrated that retinoids can interact synergistically with agents which impact on histone acetylation such as trichostatin A and butyric acid. 30, 31 To gain insight into possible molecular mechanisms underpinning the pharmacodynamic interactions between ATRA and PB in ML-1 cells, the ability of relevant doses of PB to induce histone acetylation was tested. ML-1 cells were incubated in suspen- 
Figure 4
The impact of combined PB and ATRA treatment on colony formation. ML1 cells were plated in methyl cellulose containing varying concentrations of PB and ATRA, and incubated for 9-12 days. Data represents the mean ± s.e.m. of four experiments. (b) PB alone; () ATRA alone; (̆) PB + ATRA at a fixed 1000:1 ratio. ML1 cells were plated in methyl cellulose with a fixed ratio of PB:RA (1000:1). Analysis based on 3 experiments.
sion with varying doses of PB or the known histone deacetylase inhibitor trichostatin A (0.33 m
32
) for 8 h before the isolation of histones. Western analysis of acetylated histones H3 and H4 was performed as described in Materials and methods. The results are displayed in Figure 5 . Acetylation of both histones was rapidly induced by all doses of PB tested, including 0.25 mm, which is well within the clinically achievable range.
15
Discussion
Sodium phenylbutyrate is a promising differentiating agent in the treatment of both epithelial and hematopoietic malignancies. In the ML-1 cell line, both PB and ATRA induce significant differentiation, cell cycle arrest, apoptosis, and inhibition of colony formation. When cells were exposed to PB combined with ATRA, synergistic interaction was observed with respect to differentiation, cell cycle arrest, and inhibition of colony formation. PB and ATRA do not demonstrate pharmacodynamic synergism with respect to apoptosis. The impact of ATRA and PB on cell cycle arrest is complicated, the direction of interaction varying with ATRA concentration. At low concentrations of ATRA and PB, PB antagonizes the effects of
Figure 5
Histone acetylation in response to PB administration. ML1 cells were incubated in suspension with graded doses of PB or the known histone deacetylase inhibitor trichostatin A (0.33 m) for 8 h. Histones were then isolated and resolved on SDS-PAGE before immunoblotting with antibodies directed against acetylated histones H3 (a) and H4 (b) as described in Materials and methods.
ATRA, but at higher concentrations (ATRA Ͼ 0.5 m, PB Ͼ 0.5 mm) their interaction is synergistic. Despite this varying impact on proliferation in suspension culture, PB and ATRA interact synergistically to inhibit colony formation at all doses tested.
Activity of PB in myeloid cells seems to be more closely related to its butyric acid moiety rather than its aromatic fatty acid structure, with PB activity more closely resembling BA than PA. While PA has no effect on induction of p21 WAF1/CIP1 , cell cycle arrest, apoptosis, or proliferation of myeloid leukemic cells, PB and BA have similar effects on these endpoints. 53 Like PB, BA synergizes with RA. 16 Compared to butyric acid, PB has a longer half-life and potential oral bioavailability, making it a more practical compound for clinical development.
Recent findings suggest that PB may act by impacting histone acetylation. Histone acetylation appears to alter the structure of chromatin, modulating binding and activity of transcriptional regulators. [33] [34] [35] Histone deacetylases (HD), in contrast, may be activated to mediate transcriptional repression. 36, 37 HD inhibitors activate the p21 WAF1/CIP1 promoter, leading to increased expression of this protein and subsequent cell cycle arrest. 38 PB and other differentiating agents have been shown to increase p21 WAF1/CIP1 expression. The ability of polar-planar compounds to induce differentiation is correlated with their ability to inhibit HD activity. 39 Histone acetylation may also have significant impact on retinoid activity. The HD inhibitor trichostatin A synergistically enhances retinoic acid-induced differentiation of embryonal carcinoma cells, increasing transcription from RA-responsive elements. 30 RA receptors may require changes in histone acetylation to regulate transcription. 30 The fusion receptors PML-RAR␣ and PLZF-RAR␣ in acute promyelocytic leukemia variants recruit HD activity and induce a block in differentiation; RA administration releases HD activity from PML-RAR␣. 31, 40 TSA and BA dramatically potentiated RA-induced differentiation of RA-sensitive APL cell lines, and restored retinoid responses of RA-resistant APL cell lines. 31 Although less intensively studied than BA, PB also appears to inhibit HD. 8 HD inhibition could account for many of the biological activities of PB, including its synergy with RA. The current studies document that PB can induce histone acetylation at 0.25 mm, a dose which is clinically sustainable.
2 PB plus ATRA has induced remission in an ATRA-resistant relapsed APL patient; in this case report, induction of histone acetylation in bone marrow mononuclear cells following the administration of PB was demonstrated. 41 Unlike APL, many cases of AML and MDS do not yet have identified aberrant transcriptional regulators which can be studied directly. Thus, for many or most clinical myeloid malignancies, it is not yet possible to directly measure the impact of HD inhibition on transcription of a specific relevant gene (two important exceptions are M2 AML characterized by the AML-ETO gene rearrangement, and the less common PLZF-RAR␣ APL variant, both of which also recruit HD activity). [42] [43] [44] The ML-1 cell line has no identified specific hybrid transcription factor gene; however, this cell line resembles the majority of clinical myeloid neoplasms by harboring a wild-type p53 gene. 13, 14 The activity of PB on ML-1 cells in vitro has been predictive of the activity of PB on primary bone marrow cells from patients with AML and MDS; 1 this drug has also shown preliminary clinical activity in a phase I study. 2, 15 The application of new techniques such as the use of DNA microarrays to ML-1 cells treated with HD inhibitors including PB may facilitate the identification of transcriptional regulators which are aberrantly regulated in these cells and potentially other myeloid malignancies.
Retinoids have been studied for the treatment of myelodysplastic syndromes (MDS). Two randomized trials of 13-cisretinoic acid vs observation were performed in patients with MDS. A British placebo-controlled randomized trial of 13-cisretinoic acid showed a marked 1 year survival advantage. 45 However, a subsequent randomized trial showed no effect of retinoic acid compared with placebo. 46 Treatment with ATRA alone has shown limited responses in MDS. [18] [19] [20] [21] Preliminary data have suggested the activity of ATRA when added to growth factors 47, 48 and low dose ara-C. 49 ,50 13-cis-retinoic acid may contribute to longer remissions following AML induction regimens. 51 9-cis retinoic acid, a ligand for both the RAR and RXR receptors, has shown activity in MDS. 22 ATRA has proven effective in other diseases, notably in acute promyelocytic leukemia, inducing differentiation and remissions which are karyotypically normal. 52 Clinical trials investigating the effects of PB on patients with acute myeloid leukemia and myelodysplasia have yielded promising changes in hematopoietic parameters including increased platelets and neutrophils, as well as decreased blasts.
2 Although plasma concentrations of PB 0.3-0.5 mm can be maintained safely in vivo, administration of doses yielding PB concentrations exceeding 0.5 mm are associated with dose-limiting CNS toxicity. 2 In vitro experiments have demonstrated that many of the significant effects of PB on differentiation, apoptosis, and cell cycle arrest begin to occur at concentrations above 0.5 mm.
1 Therefore, optimal clinical use of PB may require administration with other small molecules which can augment the effects of PB at doses below 0.5 mm. We have shown that in the ML-1 cell line, ATRA synergistically augments the effects of PB on differentiation, apoptosis, cell cycle arrest, and colony formation. Because of complex dose-dependent interaction in terms of cell proliferation, clinical trials combining these two molecules should include careful pharmacokinetic and pharmacodynamic analysis. The current studies suggest that the interaction between PB and ATRA is significant at concentrations of PB that are physiologically tolerated. These studies provide a rational basis for exploring the combination of PB and ATRA in clinical trials for the treatment of myeloid malignancies.
